SCHEMBL20150238

SCHEMBL20150238

Cc1cc2c(Cl)cc(Cl)nc2n1C1CCCCO1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
YTHDC1 Q96MU7 1/20 0.37
CYP4F2 P78329 2/20 0.34
CYP4A11 Q02928 2/20 0.34
GAA P10253 1/20 0.33
ATR Q13535 1/20 0.33
CYP2C19 P33261 1/20 0.33
RXRA P19793 1/20 0.32
RXRB P28702 1/20 0.32
RXRG P48443 1/20 0.32
CCNT1 O60563 1/20 0.32
CDK9 P50750 1/20 0.32
RET P07949 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
HCRTR1 O43613 1/20 0.30
HCRTR2 O43614 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20091689 0.80 YTHDC1 (0.40) YTHDC1CYP4F2CYP4A11GAAATR
SCHEMBL20699331 0.78 ALDH1A1 (0.43) YTHDC1CYP4F2CYP4A11ATRRXRA
SCHEMBL30161594 0.78 ALDH1A1 (0.43) YTHDC1CYP4F2CYP4A11ATRRXRA
SCHEMBL20092927 0.74 YTHDC1 (0.37) YTHDC1ATRCYP2C19RXRARXRB
SCHEMBL20092629 0.72 YTHDC1 (0.45) YTHDC1CYP4F2CYP4A11CYP2C19RXRA
SCHEMBL20091846 0.72 YTHDC1 (0.35) YTHDC1CYP2C19
SCHEMBL20092254 0.72 YTHDC1 (0.35) YTHDC1CYP2C19
SCHEMBL20092969 0.71 YTHDC1 (0.35) YTHDC1CYP2C19
SCHEMBL17262751 0.70 YTHDC1 (0.60) YTHDC1CYP2C19MEN1KMT2AALDH1A1
SCHEMBL31081006 0.70 YTHDC1 (0.60) YTHDC1CYP2C19MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-04-01 US disclosed
US-10647713-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2020-05-12 US disclosed
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-17 US disclosed
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 YTHDC1 2051/4885CYP4F2 3924/4885CYP4A11 4140/4885
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 YTHDC1 2051/4885CYP4F2 3924/4885CYP4A11 4140/4885
US-10647713-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 YTHDC1 2051/4885CYP4F2 3924/4885CYP4A11 4140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.